Wenke Li

Title: Innovations of Wenke Li in Milbemycin Production

Introduction

Wenke Li is an accomplished inventor based in Hubei, China. She has made significant contributions to the field of pharmaceutical production, particularly in the development of high-yield strains for milbemycin. Her innovative approaches have led to advancements that benefit both the industry and market demands.

Latest Patents

Wenke Li holds a patent for a milbemycin strain with high-yield and its application. The patent describes a strain for high-yield production of milbemycin, specifically detailing an original strain MI-W1-2017001 that undergoes mutation breeding through an atmospheric and room temperature plasma mutation method. This process results in a high-yield strain known as HZMRYB-5. The fermentation level of this new strain is improved by approximately 70% compared to the original strain. Furthermore, through optimization of the fermentation process and formulation, the fermentation level is enhanced by an additional 35%. This innovation significantly reduces the fermentation cost of the product while meeting the industrial fermentation level requirements. The optimized fermentation process achieves a ratio of A3 and A4 in the fermentation liquid of nearly 3:7 through mixed fermentation of strains MI-W1-2017001 and HZMRYB-5, effectively addressing market demands and streamlining the process steps of separation, purification, and mixing.

Career Highlights

Wenke Li is currently associated with Hubei Honch Pharmaceutical Co., Ltd., where she continues to apply her expertise in pharmaceutical innovations. Her work has not only advanced the production processes but has also contributed to the overall efficiency and cost-effectiveness of milbemycin production.

Collaborations

Wenke Li collaborates with notable colleagues, including Renwen Zhang and Wenkai Zhang, who contribute to her research and development efforts. Their teamwork enhances the innovative capabilities within their field.

Conclusion

Wenke Li's contributions to the field of pharmaceutical production, particularly through her patent on high-yield milbemycin strains, exemplify her innovative spirit and dedication to advancing industry standards. Her work continues to have a lasting impact on the efficiency and effectiveness of pharmaceutical manufacturing processes.